Transplant results in adults with Fanconi anaemia
Marc Bierings,Carmem Bonfim,Regis Peffault De Latour,Mahmoud Aljurf,Parinda A Mehta,Cora Knol,Farid Boulad,Abdelghani Tbakhi,Albert Esquirol,Grant McQuaker,Gulsan A Sucak,Tarek B Othman,Constantijn J M Halkes,Ben Carpenter,Dietger Niederwieser,Marco Zecca,Nicolaus Kröger,Mauricette Michallet,Antonio M Risitano,Gerhard Ehninger,Raphael Porcher,Carlo Dufour,EBMT SAA WP,Carmem Bonfirm,Gerard Socié,Gunham Gurman,Ardesir Ghavamzadeh,Rise-Marie Hamladji,M T van Lint,Polina Stepensky,Mickey Koh,Zubeyde Nur Ozkurt,Joan Hendrik Veelken,Donald Bunjes,Dietrich Beelen,Antonio Campos,Stephen Robinson,E Paolo Alessandrino,Ali Unal,José Maria Fernandez Navarro,G J Mufti,Andrea Velardi,Jakob Passweg,Jane Apperley,Henrik Sengeloev,Per Ljungman,Roberto Foá,Adrián Alegre,Carlos Richard Espiga,J J Cornelissen,Paolo Di Bartolomeo,Catherine Cordonnier,Paul Browne,Charlotte Jubert,Günther Gastl,Luca Pierelli,Jan-Erik Johansson,Franca Fagioli,José Moraleda,Tsila Zuckerman,Ali Bazarbachi,Petr Sedlacek,Claudia Rössig,R F Wynn,Michael Hallek,Amos Toren,Teresa Zudaire,Joahannes Clausen,Andrew Spencer,Sebastian Grazon Lopez,Rik Schots,M Komarnicki,Soledad González Muniz,Antonin Vitek,Alessandro Rambaldi,Francesco Merli,Marie Thérese Rubio,Claudia Rossig,José Rafael Cabrera Marín,Fulvio Porto,Tessa Kerre,Bernd Metzner,Jerry Stein,Yves Bertrand,Fabio Ciceri,Alicja Chybicka,J L Diez-Martin,Mohamed Bayoumy,Josu de la Fuente,Nathalie Fegueux
DOI: https://doi.org/10.1111/bjh.15006
Abstract:The outcomes of adult patients transplanted for Fanconi anaemia (FA) have not been well described. We retrospectively analysed 199 adult patients with FA transplanted between 1991 and 2014. Patients were a median of 16 years of age when diagnosed with FA, and underwent transplantation at a median age of 23 years. Time between diagnosis and transplant was shortest (median 2 years) in those patients who had a human leucocyte antigen identical sibling donor. Fifty four percent of patients had bone marrow (BM) failure at transplantation and 46% had clonal disease (34% myelodysplasia, 12% acute leukaemia). BM was the main stem cell source, the conditioning regimen included cyclophosphamide in 96% of cases and fludarabine in 64%. Engraftment occurred in 82% (95% confidence interval [CI] 76-87%), acute graft-versus-host disease (GvHD) grade II-IV in 22% (95% CI 16-28%) and the incidence of chronic GvHD at 96 months was 26% (95% CI 20-33). Non-relapse mortality at 96 months was 56% with an overall survival of 34%, which improved with more recent transplants. Median follow-up was 58 months. Patients transplanted after 2000 had improved survival (84% at 36 months), using BM from an identical sibling and fludarabine in the conditioning regimen. Factors associated with improved outcome in multivariate analysis were use of fludarabine and an identical sibling or matched non-sibling donor. Main causes of death were infection (37%), GvHD (24%) and organ failure (12%). The presence of clonal disease at transplant did not significant impact on survival. Secondary malignancies were reported in 15 of 131 evaluable patients.